Hepatitis B Virus (HBV) Global Market Report 2025

Description

Hepatitis B virus (HBV) is a liver-targeting viral infection transmitted through contact with infected blood or bodily fluids, including vertical transmission from mother to child during childbirth. The primary approach to managing HBV involves the use of antiviral medications to suppress viral replication, while vaccination plays a crucial role in prevention.

Hepatitis B virus (HBV) is categorized into acute and chronic forms. Acute hepatitis B is a short-term infection resulting from HBV, typically occurring within the first six months of exposure. The medications for acute cases aim to clear the virus from the body and prevent chronic infection. Treatment options include immune modulator drugs, antiviral medications, vaccines, and, in some cases, surgery. These treatments are administered to individuals across various age groups, including pediatrics, adults, and seniors, with medical providers, patients, and healthcare payers being involved in the healthcare process.

The hepatitis B virus (HBV) market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) market statistics, including hepatitis B virus (HBV) industry global market size, regional shares, competitors with a hepatitis B virus (HBV) market share, detailed hepatitis B virus (HBV) market segments, market trends and opportunities and any further data you may need to thrive in the hepatitis B virus (HBV) industry. This hepatitis B virus (HBV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) market size has grown strongly in recent years. It will grow from $6.71 billion in 2024 to $7.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of hepatitis b virus (hbv), growing demand for hbv diagnostics, expanding hbv vaccine coverage, rising awareness of hepatitis b virus (hbv).

The hepatitis B virus (HBV) market size is expected to see strong growth in the next few years. It will grow to $10.72 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the rise of personalized medicine, growing support from patient advocacy groups, rising vaccination programs, increase in healthcare expenditure. Major trends in the forecast period include development of new drugs, advancements in diagnostic technologies, public-private partnerships, innovative biological therapies.

The high prevalence of hepatitis B infections is anticipated to drive the growth of the hepatitis B virus market in the coming years. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), which can be prevented through vaccination. Increasing rates of hepatitis B infections are likely to elevate the demand for diagnostic tests and treatment options. For instance, in April 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2022, 254 million people were living with chronic hepatitis B, with 1.2 million new cases diagnosed each year. Consequently, the high prevalence of hepatitis B infections is expected to significantly influence the hepatitis B virus market.

An increase in the number of patients experiencing liver damage or cirrhosis is expected to drive the growth of the hepatitis B virus market in the future. Cirrhosis is a serious liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. The hepatitis B virus can impact kidney function while alleviating symptoms and side effects associated with the condition. For example, in July 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in the financial year ending 2022, England recorded 82,290 hospital admissions due to liver disease, equating to a rate of 150.6 per 100,000 people. This marks an increase from 67,458 admissions in the previous financial year ending in 2021, highlighting a growing concern about liver health within the population. Therefore, the rising incidence of liver damage or cirrhosis among patients is contributing to the growth of the hepatitis B virus market.

Prominent companies operating within the hepatitis B virus (HBV) market are placing a strong emphasis on the advancement of cutting-edge diagnostics and treatment options. One such innovation involves the utilization of highly sensitive chemiluminescent microparticle immunoassay (CMIA) technology to gain a competitive edge in the market. A case in point is Abbott Laboratories, a healthcare company based in the United States, which, in May 2022, introduced the HBsAg Next Qualitative Solution Test. This test is designed to facilitate the early detection of the Hepatitis B virus (HBV) in human serum and plasma samples. By enhancing early detection capabilities, this advanced chemiluminescent microparticle immunoassay (CMIA) not only contributes to improved patient outcomes but also safeguards the integrity of blood supplies. It enables both early detection of HBV in human serum and plasma (blood) samples and population screening, all thanks to its highly sensitive technology.

In July 2023, Brii Biosciences Ltd., a biotechnology firm headquartered in China, secured licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc., an American biotechnology company. This transaction, for an undisclosed sum, grants Brii Biosciences Ltd. access to valuable insights related to both the prevention and treatment of hepatitis B. VBI Vaccines Inc. specializes in the development of a vaccine designed to prevent infections caused by the hepatitis B virus.

Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis b virus (hbv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis b virus (hbv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Acute; Chronic
2) By Treatment: Immune Modulator Drugs; Antiviral Drugs; Vaccine; Surgery
3) By Age Group: Pediatrics; Adults; Seniors
4) By End User: Medical Providers; Patients; Healthcare Payers
Subsegments:
1) By Acute HBV: Asymptomatic Acute HBV; Symptomatic Acute HBV; Severe Acute HBV
2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive); Chronic Hepatitis B (HBeAg Negative); Chronic Hepatitis B With Compensated Liver Disease; Chronic Hepatitis B With Decompensated Liver Disease; Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmon La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28245

1. Executive Summary

2. Hepatitis B Virus (HBV) Market Characteristics

3. Hepatitis B Virus (HBV) Market Trends And Strategies

4. Hepatitis B Virus (HBV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hepatitis B Virus (HBV) Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatitis B Virus (HBV) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatitis B Virus (HBV) Market Growth Rate Analysis
5.4. Global Hepatitis B Virus (HBV) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatitis B Virus (HBV) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatitis B Virus (HBV) Total Addressable Market (TAM)

6. Hepatitis B Virus (HBV) Market Segmentation

6.1. Global Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute
Chronic
6.2. Global Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Modulator Drugs
Antiviral Drugs
Vaccine
Surgery
6.3. Global Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
Seniors
6.4. Global Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medical Providers
Patients
Healthcare Payers
6.5. Global Hepatitis B Virus (HBV) Market, Sub-Segmentation Of Acute HBV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asymptomatic Acute HBV
Symptomatic Acute HBV
Severe Acute HBV
6.6. Global Hepatitis B Virus (HBV) Market, Sub-Segmentation Of Chronic HBV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Hepatitis B (HBeAg Positive)
Chronic Hepatitis B (HBeAg Negative)
Chronic Hepatitis B With Compensated Liver Disease
Chronic Hepatitis B With Decompensated Liver Disease
Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)

7. Hepatitis B Virus (HBV) Market Regional And Country Analysis

7.1. Global Hepatitis B Virus (HBV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatitis B Virus (HBV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis B Virus (HBV) Market

8.1. Asia-Pacific Hepatitis B Virus (HBV) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis B Virus (HBV) Market

9.1. China Hepatitis B Virus (HBV) Market Overview
9.2. China Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis B Virus (HBV) Market

10.1. India Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis B Virus (HBV) Market

11.1. Japan Hepatitis B Virus (HBV) Market Overview
11.2. Japan Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis B Virus (HBV) Market

12.1. Australia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis B Virus (HBV) Market

13.1. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis B Virus (HBV) Market

14.1. South Korea Hepatitis B Virus (HBV) Market Overview
14.2. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis B Virus (HBV) Market

15.1. Western Europe Hepatitis B Virus (HBV) Market Overview
15.2. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis B Virus (HBV) Market

16.1. UK Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis B Virus (HBV) Market

17.1. Germany Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis B Virus (HBV) Market

18.1. France Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis B Virus (HBV) Market

19.1. Italy Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis B Virus (HBV) Market

20.1. Spain Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis B Virus (HBV) Market

21.1. Eastern Europe Hepatitis B Virus (HBV) Market Overview
21.2. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis B Virus (HBV) Market

22.1. Russia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis B Virus (HBV) Market

23.1. North America Hepatitis B Virus (HBV) Market Overview
23.2. North America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis B Virus (HBV) Market

24.1. USA Hepatitis B Virus (HBV) Market Overview
24.2. USA Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis B Virus (HBV) Market

25.1. Canada Hepatitis B Virus (HBV) Market Overview
25.2. Canada Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis B Virus (HBV) Market

26.1. South America Hepatitis B Virus (HBV) Market Overview
26.2. South America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis B Virus (HBV) Market

27.1. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis B Virus (HBV) Market

28.1. Middle East Hepatitis B Virus (HBV) Market Overview
28.2. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis B Virus (HBV) Market

29.1. Africa Hepatitis B Virus (HBV) Market Overview
29.2. Africa Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis B Virus (HBV) Market Competitive Landscape And Company Profiles

30.1. Hepatitis B Virus (HBV) Market Competitive Landscape
30.2. Hepatitis B Virus (HBV) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmon La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis B Virus (HBV) Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca PLC
31.4. Sanofi SA
31.5. GlaxoSmithKline PLC
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Gilead Sciences Inc.
31.9. Boehringer Ingelheim International GmbH
31.10. Mylan N.V.
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Vertex Pharmaceuticals Incorporated
31.13. Eisai Co. Ltd.
31.14. Aurobindo Pharma Limited
31.15. Apotex Corp.

32. Global Hepatitis B Virus (HBV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Market

34. Recent Developments In The Hepatitis B Virus (HBV) Market

35. Hepatitis B Virus (HBV) Market High Potential Countries, Segments and Strategies

35.1 Hepatitis B Virus (HBV) Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatitis B Virus (HBV) Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatitis B Virus (HBV) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer